| Objectives: To determine the outcome of combined transobturator tape sling
(TOT) and low dose intradetrusor injection of Abobotulinumtoxin‐A (Abobot‐
A, Dysport®) in women with mixed urinary incontinence (MUI).
Methods: This randomized, active comparator‐controlled, parallel‐group,
two‐part clinical trial was conducted on women who had positive Valsalva
leak point pressure (VLPP) + detrusor overactivity (DO), cough‐associated DO.
In Part 1, 20 women with MUI who had a failure of medical and behavioral
therapies to cure MUI, randomized in two groups receiving TOT surgery
alone, or in combination with Dysport® injection (n = 10 in each group), and
then Part 2 was initiated as a prospective open‐label on 40 more patients. We
performed cystoscopy and injected 300 U of Dysport®in 20–30 intradetrusor
injection sites in each patient.
Results: The patient's symptoms in both groups decreased significantly after
treatment. The symptoms were improved significantly in the combination therapy
group according to the International Consultation on Incontinence Questionnaireoveractive
bladder (ICIQ‐OAB) questionnaire (p<.001), and International Consultation
on Incontinence Questionnaire‐urinary Incontinence‐short form (ICIQUI‐
SF) (p=.041) in comparing with the TOT group. In Part 2, the mean score was
17.10 (4.75) for ICIQ‐UI‐SF and 9.22 (2.89) for ICIQ‐OAB before the treatment.
Twelve weeks after the intervention, the median (interquartile range: IQR) of ICIQOAB
symptoms (2.0 [3.0]; p <.001) and ICIQ‐UI‐SF decreased, too (1. 0 [2.0];
p <.001). Considering improvement using Patient Global Impression of Improvement
scale, 46 (92.0%) stated that they had significant subjective improvement of
their symptoms.
Conclusions: Combination therapy was accompanied with a promising effect
in the patients with MUI according to the results of standardized questionnaires.
However, further studies with controlled arms are recommended. |